Hidehito Horinouchi: Telisotuzumab Vedotin and Osimertinib in EGFR-Mutated NSCLC
Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X about a recent paper by him and colleagues published in Annals of Oncology:
“Phase 1b study of telisotuzumab vedotin + osimertinib in patients with c-Met overexpressing, EGFR-m NSCLC after progression on prior osi:
- MET ADC
- ORR 50.0%, mPFS 7.4 mo (95% CI: 5.4, NR) per ICR.”
Authors: Hidehito Horinouchi et al.
More posts featuring Hidehito Horinouchi.
Hidehito Horinouchi is the Assistant Chief of the National Cancer Center Hospital. He also serves as the Secretary General of the Lung Cancer Study Group, Japan Clinical Oncology Group, and the Deputy Chief of the Center for Education and Professional Career Development at the National Cancer Center Hospital.
He specializes in multimodal treatment strategies, including medical, surgical, and radiation oncology, for patients with thoracic malignancies.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023